|1.||Del Ry, S: 9 articles (02/2015 - 01/2008)|
|2.||Kangawa, Kenji: 8 articles (04/2015 - 06/2002)|
|3.||Cabiati, M: 8 articles (02/2015 - 01/2008)|
|4.||Espiner, Eric A: 7 articles (02/2015 - 12/2002)|
|5.||Giannessi, D: 7 articles (12/2013 - 01/2008)|
|6.||Sangaralingham, S Jeson: 5 articles (06/2015 - 02/2011)|
|7.||Burnett, John C: 5 articles (06/2015 - 02/2011)|
|8.||Caselli, C: 5 articles (02/2015 - 01/2012)|
|9.||Prickett, Timothy C R: 5 articles (02/2015 - 08/2007)|
|10.||Prescimone, T: 5 articles (02/2015 - 01/2012)|
02/01/2011 - "Studies have established the potent antifibrotic and antiproliferative properties of C-type natriuretic peptide (CNP); however, the relationship between circulating CNP, LV fibrosis, and associated changes in LV function with natural aging are undefined. "
09/01/2012 - "Increased urinary C-type natriuretic peptide excretion may be an early marker of renal tubulointerstitial fibrosis."
11/01/2011 - "Urinary C-type natriuretic peptide excretion: a potential novel biomarker for renal fibrosis during aging."
02/01/2011 - "The aging heart, myocardial fibrosis, and its relationship to circulating C-type natriuretic Peptide."
02/01/2011 - "C-type natriuretic peptide and cardiac fibrosis."
|2.||Pulmonary Hypertension (Ayerza Syndrome)
12/01/2004 - "C-type natriuretic peptide ameliorates monocrotaline-induced pulmonary hypertension in rats."
09/26/2011 - "C-type natriuretic peptide does not attenuate the development of pulmonary hypertension caused by hypoxia and VEGF receptor blockade."
03/01/2006 - "[The expression and significance of urotensin II, nitric oxide, and C-type natriuretic peptide in hypoxia-induced pulmonary hypertension in rats]."
08/01/1997 - "Therefore, we studied, in 1-day-old piglets exposed to hypoxia (fraction of inspired O2 0.10) for 3 or 14 days to induce pulmonary hypertension, 1) ANF release by measuring circulating levels of ANF by radioimmunoassay in pulmonary artery and veins, 2) pulmonary vascular reactivity to ANF using isolated perfused lungs, and 3) binding characteristics by examining the concentration dependence of ANF binding and competitive binding of 125I-labeled ANF with ANF, brain natriuretic peptide, C-type natriuretic peptide, and the specific ligand for ANF clearance receptor on microsomes from pulmonary arteries (down to 100 microns). "
03/01/2006 - "To investigate the alteration of plasma and lung tissue homogenate urotensin II (U-II), nitric oxide (NO) and C-type natriuretic peptide (CNP) levels in rats with hypoxia-induced pulmonary hypertension (HPH) and to study the role of these factors and oxygen treatment in the development of HPH. "
|3.||Postural Orthostatic Tachycardia Syndrome
06/01/2015 - "Total peripheral vascular resistance, cardiac output, and plasma C-type natriuretic Peptide level in children with postural tachycardia syndrome."
01/01/2015 - "This study was designed to investigate predictive value of plasma C-type natriuretic peptide (CNP) in the therapeutic efficacy of metoprolol on postural tachycardia syndrome (POTS) in children. "
06/01/2015 - "To investigate the total peripheral vascular resistance (TPVR), cardiac output (CO), and plasma C-type natriuretic peptide (CNP) levels in children with postural tachycardia syndrome (POTS) during supine, upright, and return to supine. "
01/01/2015 - "Plasma C-type natriuretic peptide as a predictor for therapeutic response to metoprolol in children with postural tachycardia syndrome."
|4.||Acute Kidney Injury (Acute Renal Failure)
11/04/2014 - "The purpose of the present study was to identify the effect of C-type natriuretic peptide (CNP), a selective activator of NPR-B, on the IR-induced acute kidney injury and its mechanisms involved. "
11/04/2014 - "C-type natriuretic peptide ameliorates ischemia/reperfusion-induced acute kidney injury by inhibiting apoptosis and oxidative stress in rats."
12/01/2003 - "[The possible novel treatment of achondroplasia, C-type natriuretic peptide (CNP)]."
01/01/2016 - "C-Type Natriuretic Peptide Analog as Therapy for Achondroplasia."
12/15/2012 - "C-type natriuretic peptide (CNP) is a potent stimulator of endochondral bone growth and represents a potential therapy for achondroplasia. "
02/01/2015 - "C-type natriuretic peptide plasma levels are elevated in subjects with achondroplasia, hypochondroplasia, and thanatophoric dysplasia."
06/01/2005 - "We previously reported that C-type natriuretic peptide (CNP) stimulates endochondral ossification and corrects the reduction in body length of achondroplasia model mouse with constitutive active fibroblast growth factor receptor 3 (FGFR-3). "
|3.||Brain Natriuretic Peptide (Natrecor)
|4.||Atrial Natriuretic Factor (ANF)
|6.||Guanylate Cyclase (Guanylyl Cyclase)
|7.||Messenger RNA (mRNA)
|8.||Interleukin-1beta (Interleukin 1 beta)
|9.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|10.||Interleukin-6 (Interleukin 6)
|4.||Angioplasty (Angioplasty, Transluminal)